AptaBio Therapeutics Inc. (KOSDAQ:293780)

South Korea · Delayed Price · Currency is KRW

4,495.00

-175.00 (-3.75%)

Nov 13, 2026, 3:30 PM KST

Market Cap	126.28B -33.6%
Revenue (ttm)	4.75B +52.9%
Net Income	-14.87B
EPS	-540.42
Shares Out	28.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,149
Open	4,670.00
Previous Close	4,670.00
Day's Range	4,410.00 - 4,670.00
52-Week Range	3,870.00 - 10,890.00
Beta	0.90
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About AptaBio Therapeutics

AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical nee... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2009

Employees 44

Stock Exchange KOSDAQ

Ticker Symbol 293780

Full Company Profile

Financial Performance

In 2025, AptaBio Therapeutics's revenue was 3.70 billion, an increase of 10.02% compared to the previous year's 3.36 billion. Losses were -16.35 billion, -44.36% less than in 2024.

Financial Statements